Table 4.
EULAR response, low disease activity and remission rates during TNF inhibitor treatment of the rheumatoid arthritis cohort
| 3 months | 6 months | 12 months | |
|---|---|---|---|
| Good response (%) |
39.5 |
45.8 |
50.5 |
| Moderate response (%) |
49.5 |
39.8 |
31.9 |
| Nonresponse (%) |
14 |
14.4 |
17.6 |
| DAS28(4v)-CRP <3.2 (%) |
42.3 |
50.9 |
54.9 |
| Low disease activity (%) |
18.5 |
20.5 |
17.6 |
| DAS28 remission |
53 (23.9%) |
65 (30.1%) |
102 (37.4%) |
| Boolean remission | 7 (3.2%) | 23 (10.6%) | 27 (9.9%) |
EULAR, European League Against Rheumatism, TNF, tumour necrosis factor; DAS28(4v)-CRP, disease activity score based on joints using four variables and including C-reactive protein as the inflammatory marker; DAS28, disease activity score based on 28 joints.